Ansa Biotechnologies hauled in a total of $54.4 million in an oversubscribed series B financing round that will be used to expand the company’s DNA synthesis production capacity in the U.S.
Ansa snares $54.4M in series B financing to boost its DNA synthesis platform
Latest from Blog
FDA Reverses Course, Approves First mRNA Flu Shot MedNews
FRIDAY, Aug. 7, 2026 The U.S. Food and Drug Administration (FDA) has approved the first flu vaccine built on messenger RNA (mRNA) technology, months after the a Post Views: 0
Therapy Dogs Aid Stroke Rehab MedNews
FRIDAY, Aug. 7, 2026 Pets make everything better including stroke rehabilitation, a new study says. Patients recovering from a recent stroke became more engaged Post Views: 0
Can Yoga Calm A Grumpy Gut? MedNews
FRIDAY, Aug. 7, 2026 For millions of people living with irritable bowel syndrome, or IBS, relief may come from an unexpected place the yoga mat. IBS causes abdo Post Views: 0
Making School Lunches Healthy Is Great – If Kids Will Eat What’s on the Tray
Loretta: West Virginia banned dyes and started a farm-to-table program for school cafeterias. Will that momentum carry over to the lunch line? Post Views: 2
A third clinic settles with DOJ over trans care
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. It’s so hot that it’s open fire hydrant season in New York City. Read